OM
ARQT icon

Opaleye Management’s Arcutis Biotherapeutics ARQT Stock Holding History

Opaleye Management’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1,960,000
Closed -$6.33M – 53
2023
Q4 		$6.33M Buy
+1,960,000
New +$5.33M 1.68% 16
2023
Q2 		– Sell
-502,000
Closed -$5.52M – 48
2023
Q1 		$5.52M Buy
+502,000
New +$7.26M 1.65% 17

Other funds holding ARQT

Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return

Opaleye Management's ARQT Position: Q1 2024 in Review

Opaleye Management sold out of Arcutis Biotherapeutics (ARQT) in Q1 2024, closing a stake of 1,960,000 shares — an estimated $6.33M sold.

Opaleye Management first reported a position in ARQT in Q1 2023 and held it in 2 quarters. The position peaked at $6.33M in Q4 2023. 168 funds tracked by Wall St. Rank hold ARQT as of Q1 2024.

  • Opaleye Management reported no remaining Arcutis Biotherapeutics position as of Q1 2024 after selling out during the quarter.
  • Opaleye Management sold 1,960,000 Arcutis Biotherapeutics shares in Q1 2024, an estimated $6.33M.
  • Opaleye Management first reported a position in Arcutis Biotherapeutics in Q1 2023 and held it in 2 quarters.
  • Opaleye Management's Arcutis Biotherapeutics position peaked at $6.33M in Q4 2023.
  • 168 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q1 2024.

Based on Opaleye Management's 13F filing for Q1 2024, filed 15 May 2024.